Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
Analysts at major Wall Street banks are getting more cautious on chip darling ASML, raising concerns about the critical chip equipment maker’s demand outlook.